Fumie Kajikawa

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models

U. Hoch, S. Kashimoto, J. Silverman, 2009, Cancer Chemotherapy and Pharmacology.

Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice.

S. Kashimoto, S. Nakamura, K. Nakata, 1991, Cancer research.